The nucleosome is the primary repeating unit of DNA organization in chromat
in, and cell death may lead to increased levels of circulating nucleosomes
in plasma (PNLs) in various circumstances such as inflammation, pulmonary e
mbolism, autoimmune disease, and cancer. Cell death can also be induced by
chemotherapeutic agents. We investigated PNLs in 99 patients with primary b
reast cancer, 26 with recurrent disease, 11 with benign breast disease, and
27 with other histological types of cancer. In 18 patients with recurrent
breast cancer who received docetaxel (D, 60 mg/m(2)) every 3 weeks as secon
d line therapy after an anthracycline-based regimen, PNLs were investigated
before and during the administration of D. One hundred and seventy-four he
althy controls (111 females, 63 males) without any evidence of disease were
also investigated. PNLs were detected using the cell death detection ELISA
(plus) kit. PNLs were significantly higher in patients with primary breast
cancer (mean +/- SD: 0.135 +/-0.213) and in recurrent breast cancer (0.182
+/-0.196) as compared with healthy female controls (0.010 +/-0.012) (p <0.0
1). In patients with primary breast cancer, no correlation was found betwee
n PNLs and clinicopathological characteristics. On the other hand, PNLs wer
e decreased after mastectomy (p <0.05). Patients with other histological ty
pes of cancer (0.244 +/-0.383) also showed significantly higher PNLs as com
pared to healthy controls (p <0.01), and PNLs were elevated independently o
f the histological type of cancer. In patients with recurrent breast cancer
, PNLs showed a transient increase 24 h after the administration of D, and
these increases correlated with the degree of subsequent leukopenia. In a f
ollow-up study, pretreatment baseline PNLs decreased markedly when a respon
se was obtained, whereas there was no decrease in either stable disease or
progressive disease. Thus, increased PNLs were found in cancer patients, an
d PNLs seem to be a sensitive marker of cell death that could be predictive
of both Leukopenia and response to chemotherapy.